|  |  |
| --- | --- |
| DEPARTMENT OF HEALTH SERVICES Division of Care and Treatment Services  F-24277 (05/2024) | STATE OF WISCONSIN 42 CFR483.420(a)(2)  DHS 134.31(3)(o)  DHS 94.03 & 94.09  §§ 51.61(1)(g) & (h) |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| INFORMED CONSENT FOR MEDICATIONDosage and / or Side Effect information last revised on 08/21/2020 Completion of this form is voluntary. If informed consent is not given, the medication cannot be administered without a court order unless in an emergency.  This consent is maintained in the client’s record and is accessible to authorized users. | | | | | | | | | |
| Name – Patient / Client (Last, First MI)       , | | | | | | ID Number | | Living Unit | Date of Birth |
| Name – Individual Preparing This Form | | | Name – Staff Contact | | | | | Name / Telephone Number – Institution | |
| MEDICATION CATEGORY | **MEDICATION** | | | RECOMMENDED **DAILY TOTAL DOSAGE RANGE** | | | | | ANTICIPATED DOSAGE RANGE |
| Antidepressant (SSRI) | Paxil; Paxil CR; Pexeva; Brisdelle  (paroxetine) | | | Immediate release (Paxil, Pexeva, Brisdelle): 5 mg – 60 mg  Extended release (Paxil CR): 12.5 mg- 62.5 mg | | | | |  |
| The anticipated dosage range is to be individualized, may be above or below the recommended range but no medication will be administered without your informed and written consent. Recommended daily total dosage range of manufacturer, as stated in *Physician’s Desk Reference* (PDR) or another standard reference.  This medication will be administered  Orally  Injection  Other – Specify: | | | | | | | | | |
| Reason for Use of Psychotropic Medication and Benefits Expected (note if this is ‘Off-Label’ Use) Include DSM-5 diagnosis or the diagnostic impression (“working hypothesis.”) | | | | | | | | | |
|  | | | | | | | | | |
| **2. Alternative mode(s) of treatment other than OR in addition to medications include** Note: Some of these would be applicable only in an inpatient environment. | | | | | | | | | |
| Environment and/or staff changes | | | | | Rehabilitation treatments/therapy (OT, PT, AT) | | | | |
| Positive redirection and staff interaction | | | | | Treatment programs and approaches (habilitation) | | | | |
| Individual and/or group therapy | | | | | Use of behavior intervention techniques | | | | |
| **Other Alternatives**: | | | | | | | | | |
|  | | | | | | | | | |
| 3. Probable consequences of NOT receiving the proposed medication are | | | | | | | | | |
| Impairment of  Work Activities | | Family Relationships | | | | | Social Functioning | | |
|  | |  | | | | |  | | |
| Possible increase in symptoms leading to potential | | | | |  | | | | |
| Use of seclusion or restraint | | | | | Limits on recreation and leisure activities | | | | |
| Limits on access to possessions | | | | | Intervention of law enforcement authorities | | | | |
| Limits on personal freedoms | | | | | Risk of harm to self or others | | | | |
| Limit participation in treatment and activities | | | | |  | | | | |
| **Other Consequences**: | | | | | | | | | |
| Note: These consequences may vary depending upon whether or not the individual is in an inpatient setting. It is also possible that in unusual situations, little or no adverse consequences may occur if the medications are not administered. | | | | | | | | | |

See Page 2

| F-24277 | Medication : Paxil; Paxil CR; Pexeva - (paroxetine ) |
| --- | --- |
| Possible side effects, warnings, and cautions associated with this medication are listed below. This is not an all-inclusive list but is representative of items of potential clinical significance to you. For more information on this medication, you may consult further with your physician or refer to a standard text, such as the PDR. As part of monitoring some of these potential side effects, your physician may order laboratory or other tests. The treatment team will closely monitor individuals who are unable to readily communicate side effects in order to enhance care and treatment. | |
| Continued – Possible side effects, warnings, and cautions associated with this medication.Most Common Side Effects: excessive sweating; belching; decreased appetite; consitpation; diarrhea; dizziness; decreased sexual ability or desire; difficulty with ejaculation; excess air or gas in stomach or intestines; heartburn; nervousness; headache; difficulty urinating; runny or stuffy nose; sleepiness or unusual drowsiness; stomach discomfort, upset, or pain; trembling or shaking; difficulty falling or staying asleep; sleeping too much. | |
| **Less Common Side Effects:** agitation; chest pain; chills; cold sweats; confusion; difficulty breathing; chest congestion; faintness or lightheadedness when getting up from a lying or sitting position; fast, pounding, or irregular heartbeat or pulse; muscle pain or weakness; skin rash; abnormal dreams; anxiety; bladder pain; body aches; change in sense of taste; changes in vision; cloudy urine (urinary tract infection); confusion; difficulty moving; feeling sad or empty; drugged feeling; feeling of being outside of reality; feeling of warmth or heat; flushing or redness of skin, especially on face and neck; frequently feeling the need urinate; increased bleeding or bruising; increase in normal and abnormal body movements; increased appetite; itchy skin; lack of emotion; loss of interest or pleasure; loss of memory; feeling of lump in throat; menstrual changes; menstrual pain or cramps; muscle twitching or jerking; pain during sexual intercourse; increased sensitivity of the skin to the sun; sunburns; thick, white vaginal discharge with no odor or with a mild odor; tingling, burning, or prickling sensations of the skin; trouble concentrating; voice changes; watering of eyes; weight gain or loss. | |
| **Rare Side Effects:** Although rare, contact your physician as soon as posible if any of the following occur: difficulty moving muscles; bigger, dilated, or enlarged pupils [black part of eye]; difficulty speaking; inability to move eyes; incomplete, sudden, or unusual body or facial movements; increased sensitivity of eyes to light; low blood sodium (confusion, convulsions [seizures], drowsiness, dryness of mouth, increased thirst, lack of energy); red or purple patches on skin; serotonin syndrome (confusion, diarrhea, fever, poor coordination, restlessness, shivering, sweating, talking and acting with excitement you cannot control, trembling or shaking, twitching); chest pain; abnormal heartbeat; hallucinations; migraine headaches; difficulty breathing; redness or swelling of the tongue or face; yellowing of the skin or eyes. | |
| **Caution**   * **Alcohol** Avoid drinking alcoholic beverages while you are taking paroxetine, as the consumption of alcohol with paroxetine could worsen side effects such as dizziness and drowsiness. * **Driving and operating heavy machinery** This medicine may cause some people to become drowsy, to have trouble thinking, or to have problems with movement. Make sure you know how you react to paroxetine before you drive, use heavy machinery, or do anything else that could be dangerous if not fully alert. * **Bleed risk** Increased risk of bleeding if used with aspirin, NSAIDs (naproxen, ibuprofen), warfarin, or other anticoagulants. * **Psychosis/ Mania** May worsen psychosis in some patients or precipitate shift to mania or hypomania in patient with bipolar disorder. * **Withdrawal** Abrupt discontinuation or interruption may cause withdrawal symptoms. Please speak with your doctor before stopping this medication. * **Serotonin syndrome** Serotonin syndrome (SS) is a potentially life-threatening syndrome that has occurred with serotonergic agents (eg, SSRIs, SNRIs), particularly when used in combination with other serotonergic agents (eg, triptans, TCAs, fentanyl, lithium, tramadol, buspirone, St John's wort, tryptophan) or agents that impair metabolism of serotonin (eg, MAO inhibitors intended to treat psychiatric disorders, other MAO inhibitors [ie, linezolid and intravenous methylene blue]). Monitor patients closely for signs of SS such as mental status changes (eg, agitation, hallucinations, delirium, coma); autonomic instability (eg, tachycardia, labile blood pressure, diaphoresis); neuromuscular changes (eg, tremor, rigidity, myoclonus); GI symptoms (eg, nausea, vomiting, diarrhea); and/or seizures. Discontinue treatment (and any concomitant serotonergic agent) immediately if signs/symptoms arise. * **Decreased sexual function** This medication may cause or worsen sexual desire or function. If this becomes bothersome, please speak with your doctor about your concerns. * **Seizures** This medication, in rare cases, may make it more likely to experience a seizure. This medication should be used with caution in those who have a history of seizures. * **Fractures** Bone fractures have been associated with antidepressant treatment. * **Effects on Vision** May cause mild pupillary dilation, which can lead to an episode of narrow-angle glaucoma in susceptible individuals. | |
| **Warning: [Black Box Warning]: Antidepressants and Suicidality:**  Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in short term studies in children, adolescents, and young adults with major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of this drug or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. This drug is not approved for use in pediatric patients.  MONITORING RECOMMENDATIONS RELATED TO BLACK BOX DATA—Close observation for suicidal thinking or unusual changes in behavior. | |
| See standard reference text for an all-inclusive list of side effects. | |
| By my signature below, I GIVE consent for the named medication on Page 1 and anticipated dosage range. My signature also indicates that I understand the following:   1. I can refuse to give consent or can withdraw my consent at any time with written notification to the institution director or designee. This will not affect my right to change my decision at a later date. If I withdraw consent after a medication is started, I realize that the medication may not be discontinued immediately. Rather, it will be tapered as rapidly as medically safe and then discontinued so as to prevent an adverse medical consequence, such as seizures, due to rapid medication withdrawal. 2. Questions regarding this medication can be discussed with the Interdisciplinary Team, including the physician. The staff contact person can assist in making any necessary arrangements. 3. Questions regarding any behavior support plan or behavior intervention plan, which correspond with the use of the medication, can be directed to the client’s social worker, case manager, or psychologist. 4. I have the right to request a review at any time of my record, pursuant to § 51.30(4)(d) or § 51.30(5)(b). 5. I have a legal right to file a complaint if I feel that client rights have been inappropriately restricted. The client’s social worker, case manager, or agency/facility client rights specialist may be contacted for assistance. 6. My consent permits the dose to be changed within the **anticipated dosage range** without signing another consent. 7. I understand the reasons for the use of the medication, its potential risks and benefits, other alternative treatment(s), and the probable consequences that may occur if the proposed medication is not given. I have been given adequate time to study the information and find the information to be specific, accurate, and complete. 8. This medication consent is for a period effective immediately and not to exceed fifteen (15) months from the date of my signature. The need for and continued use of this medication will be reviewed at least quarterly by the Interdisciplinary Team. The goal, on behalf of the client, will be to arrive at and maintain the client at the minimum effective dose. | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **SIGNATURES** | | | | | **DATE SIGNED** |
| Client – If Presumed Competent to Consent/Parent of Minor/Guardian (POA-HC) | | | Relationship to Client  Self  Parent  Guardian (POA-HC) | |  |
| Staff Present at Oral Discussion | | | Title | |  |
| Client / Parent of Minor / Guardian (POA-HC) Comments | | | | | |
| **As parent/guardian (POA-HC) was not available for signature, he/she was verbally informed of the information in this consent.** | | | | |
| **Verbal Consent** | | | | |
| Obtained by – PRINT – Staff Name | Date Obtained | | Written Consent Received Yes  No | |
| Obtained from – PRINT – Parent / Guardian (POA-HC) Name | Date Expires | | Date Received | |